Related Funding Opportunities

2022 Opportunities ▼

  • NOT-CA-22-063, Understanding the Basic Mechanisms of Immune-related Adverse Events (irAEs) in Cancer Immunotherapy
  • NOT-CA-22-072, Seeking Input for the National Cancer Institute (NCI) on Advancing Research in Immuno-oncology, Immunoprevention, and/or Immunotherapy
  • RFA-CA-22-016, Pediatric Immunotherapy Network (PIN) (U01 Clinical Trial Optional)
  • NOT-CA-22-074, Cancer Adoptive Cellular Therapy Network (Can-ACT) for Adult Cancers (UG3/UH3 Clinical Trial Required)
  • NOT-CA-22-075, Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical Trial Required)
  • NOT-CA-22-076, Cancer Adoptive Cellular Therapy Network (Can-ACT) Coordinating Center (U24 Clinical Trial Not Allowed)
  • PAR-22-099, Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)

2021 Opportunities ▼

  • NOT-CA-21-068, Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
  • NOT-CA-21-069, Coordinating Center for Canine Cancer Immunotherapy Network (K9CIN; U24 Clinical Trial Not Allowed)
  • NOT-CA-21-097, Notice of Pre-application Webinar for Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT)
  • RFA-CA-21-037, 3D Technologies to Accelerate HTAN Atlas Building Efforts (UH2 Clinical Trial Not Allowed)
  • RFA-CA-21-041, Pancreatic Ductal Adenocarcinoma (PDAC) Stromal Reprogramming Consortium (PSRC) (U01 Clinical Trial Not Allowed)
  • RFA-CA-21-042, Pancreatic Ductal Adenocarcinoma Stromal Reprogramming Consortium Coordinating and Data Management Center (PSRC CDMC) (U24 Clinical Trial Not Allowed)
  • RFA-CA-21-050, Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
  • RFA-CA-21-051, Coordinating Center for Canine Cancer Immunotherapy Network (K9CIN; U24 Clinical Trial Not Allowed)

2020 Opportunities ▼

  • PAR-20-295, Clinical Translation of Activated Optical Fluorescence Methods and Technologies for Sensitive Cancer Detection in Vivo (R01 Clinical Trial Optional)
  • NOT-CA-21-008, Availability of Administrative Supplements to Adapt/Repackage Visualization Methods for Enhancing Cancer Moonshot Data

2019 Opportunities ▼

  • RFA-CA-19-049, Revision Applications for Mechanisms of Cancer Drug Resistance (R01 Clinical Trial Not Allowed)
  • RFA-CA-19-050, Revision Applications for Mechanisms of Cancer Drug Resistance (U01 Clinical Trial Not Allowed)
  • RFA-CA-19-051, Revision Applications for Mechanisms of Cancer Drug Resistance (U54 Clinical Trial Not Allowed)
  • RFA-CA-19-052, Revision Applications for Mechanisms of Cancer Drug Resistance (P01 Clinical Trial Not Allowed)
  • RFA-CA-19-053, Revision Applications for Mechanisms of Cancer Drug Resistance (P50 Clinical Trial Not Allowed)